2. Contents
• Mission & Vision
• Novartis India
• History
• People
• Top 10 Brands
• Current Alliance
• Product Mix
• Presence
• Financial Data
• Stock Price
• R & D
• References
3. Mission & Vision
• We want to discover, develop and successfully
market innovative products to prevent and
cure diseases, to ease suffering and to
enhance the quality of life.
• We also want to provide a shareholder return
that reflects outstanding performance and to
adequately reward those who invest ideas and
work in our company.
4. Novartis India
Mission
Innovative products, Outstanding performance,
Ideas and work.
Vision
A better today and tomorrow for patients.
Directors
Christopher Snook (Chairman)
Ranjit Shahani (Vice Chairman & M.D.)
5. History
1996 – The shareholders of Sandoz and Ciba-
Geigy approve of the merger.
1997- Novartis announces to acquire crop
protection business of Merck & co.
2000 - Novartis seeds are merged with
Astrazeneca’s agribusiness operations to form
Syngenta.
2001- FDI grants approval of Glivec.
2003- Novartis unites it’s generics business under
one single global brand - Sandoz.
20. Pharmaceutic
als
Alcon Sandoz Vaccines and
Diagnostics
Consumer
Health
United States 32% 10 392 39% 4 016 32% 2 786 40% 746 17% 652
Europe 32% 10 238 27% 2 710 49% 4 225 35% 658 50% 1 877
Asia/Africa/
Australasia
26% 8 434 23% 2 395 12% 1 057 15% 273 21% 777
Canada and
Latin America
10% 3 089 11% 1 104 7% 634 10% 181 12% 429
Total 32 153 10 225 8 702 1 858 3 735
Established
Markets
77% 24 778 76% 7 805 74% 6 402 77% 1 434 65% 2 415
Emerging
Growth
Markets
23% 7 375 24% 2 420 26% 2 300 23% 424 35% 1 320
Total 32 153 10 225 8 702 1 858 3 735
2012 NET SALES BY REGION AND SEGMENT
21. 2012 NET SALES BY SEGMENT
% USD in millions
Pharmaceuticals 57 32 153
Alcon 18 10 225
Sandoz 15 8 702
Vaccines and Diagnostics 3 1858
Consumer Health 7 3735
Total 56 673
22. Pharmaceuticals :-
Sales : Rs. 330.5 Cr. (Half year ended September 2012)
Growth : 11.8%
OTC :-
Sales : Rs. 48.2 cr. (Half year ended September 2012)
Growth : - 10.07%
Animal Health :-
Sales : Rs. 47.6 Cr. (Half year ended September 2012)
Growth : 16.95%
Sandoz(Generics):-
Sales : Rs. 30.6 Cr. (Half year ended September 2012)
Growth : 5.15%
Net sales (India)
24. ROLE OF R&D
• Targeting rare and neglected diseases
• Ethical research
• Responsible R&D
25. R&D LOCATIONS OF NOVARTIS
• NIBR PHARMA DEVELOPMENT
-EMERYVILLE US -INDIA
-LA JOLLA CALIFORNIA US -CHINA
- FORT WORTH TX USA -JAPAN
-CAMBRIDGE US
-EAST HANOVER US
-HORSHAM UK VACCINES AND DIAGNOSTIC
-BASEL SWITZERLAND -US
-SIENA ITALY -ITALY
-SINGAPORE
-SHANGHAI CHINA